Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Tremfya rises from Stelara’s ashes; Pfizer uses mature brands as testbeds; Chinese science shines in Q3 deals; autoimmune win and setback for Argenx; and Japan looks to restore biopharma competitiveness.
Scrip - October 19, 2026

Bipartisan House Bill Would Exempt Ostomy, Urological Supplies From Medicare Competitive Bidding
Bipartisan House legislation would exempt ostomy and urological supplies from Medicare competitive bidding for five years, as CMS moves to include them in the program’s next round. Groups supporting the bill say these products are unique and not suitable for the program.
Medtech Insight - October 16, 2026

Edwards Mitral Valve Device Linked To One Death, One Injury, FDA Warns
The US FDA has issued an early alert for some Commander M delivery systems used with Edwards Lifesciences’ Sapien M3 transcatheter mitral valve replacement system after reports of balloon ruptures during inflation. The company reports three incidents, including one death and one serious injury.
Medtech Insight - October 16, 2026

Cardiac Device Trials To Watch: Four Readouts That Test Whether Early Signals Hold Up
Abbott's TECTONIC data at TCT, BiVACOR's artificial heart expansion, Medtronic's Sphere-9 VT push and Corvia's RESPONDER-HF headline a pivotal stretch for cardiac device innovation.
Medtech Insight - October 16, 2026

US OTC Eye Drop Market Expands With Apraclonidine As FDA Approves Alcon’s Brytly
As OTC industry looks for approval of ACNU switches to treat chronic conditions such as high cholesterol and diabetes, FDA approves Alcon’s conventional switch for Brytly brand apraclonidine 0.125% to relieve redness due to minor eye irritations.
HBW Insight - October 18, 2026

Mahl Takes Charge At Fresenius Kabi As Antonelli Departs
Fresenius Kabi has announced a leadership change that will see Marc-Alexander Mahl take over responsibility of the business from current CEO Pierluigi Antonelli at the start of November. Meanwhile, Fresenius chief financial officer Sara Hennicken has seen her contract extended by another five years.
Generics Bulletin - October 16, 2026

Faster Decisions And Earlier Access: UK Generics Industry Welcomes MHRA’s 2030 Targets
Medicines UK has welcomed targets set as part of the newly-unveiled MHRA Strategy 2030, including making faster decisions on generics and biosimilars and also deepening engagement with international markets such as India.
Generics Bulletin - October 16, 2026

Beyond AlphaFold: Immuto Bets Protein Conformations Hold The Next Cancer Targets
Immuto Scientific bets reading protein shapes on living tumor cells can steer antibodies to targets that genomics and expression profiling miss and the company has partnered Daiichi Sankyo and UW-Madison on this basis, Immuto co-founder Daniel says.
In Vivo - October 16, 2026

ProKidney Is Betting A Cell Therapy Phase III Readout Can Fund Its Way To Market
Pivotal data are due in the second quarter of 2027, around when the company’s money is guided to run out. CEO Bruce Culleton spoke to In Vivo on the science, the procedure and the balance sheet.
In Vivo - October 16, 2026